Senores Pharmaceuticals IPO Details: The Senores Pharmaceuticals IPO is set to open on December 20, 2024, and close on December 24, 2024. This IPO follows a Book Built Issue format, with the company aiming to raise approximately ₹582.11 crores. The offering includes a fresh issue of ₹500 crores and an offer for sale of up to 21,00,000 equity shares, each with a face value of ₹10.
The price band for the Senores Pharmaceuticals IPO is ₹372 to ₹391 per share. The retail investor quota is set at 10%, while Qualified Institutional Buyers (QIB) have a 75% allocation, and High Net-Worth Individuals (HNI) are allotted 15%. The IPO is expected to list on the BSE and NSE on December 30, 2024, with allotment finalization scheduled for December 26, 2024.
In terms of financial performance, the company reported revenue of ₹217.34 crores in 2024, a significant increase from ₹39.02 crores in 2023. However, it posted a loss of ₹32.71 crores in 2024, contrasting with a profit of ₹8.43 crores in 2023. Considering these financials, investors may view this IPO as a potential long-term opportunity.
Senores Pharmaceuticals IPO Objectives:
The Company proposes to utilise the Net Proceeds towards funding the following objects:
- Investment in one of the Subsidiaries, Havix Group, Inc. d/b/aAavis Pharmaceuticals(“Havix”), to fund capital expenditure requirements for setting up a manufacturing facility for the production of sterile injections in the Atlanta Facility;
- Repayment/pre-payment, in full or in part, of certain borrowings availed by the Company;
- Investment in the Subsidiary, namely, Havix, for re-payment/pre-payment in whole or part of certain borrowings availed by such Subsidiary;
- Funding the working capital requirements of the Company;
- Investment in the Subsidiaries, namely, Senores Pharmaceuticals Inc. (“SPI”)and Ratnatris Pharmaceutical Private Limited (“Ratnatris”), to fund their working capital requirements.
- Funding inorganic growth through acquisition and other strategic initiatives and general corporate purposes.
Senores Pharmaceuticals IPO Review (Apply or Not)
- May Apply
Senores Pharmaceuticals IPO Date & Price Band Details:
| IPO Open Date: | December 20, 2024 |
| IPO Close Date: | December 24, 2024 |
| Face Value: | ₹10 Per Equity Share |
| IPO Price Band: | ₹372 to ₹391 Per Share |
| Issue Size: | Approx ₹582.11 Crores, 1,48,87,723 Equity Shares |
| Fresh Issue: | Approx ₹500 Crores, 1,27,87,723 Equity Shares |
| Offer for Sale: | Approx ₹82.11 Crores, 1,27,87,723 Equity Shares |
| Issue Type: | Book Built Issue |
| IPO Listing: | BSE & NSE |
| Retail Quota: | Not more than 10% |
| QIB Quota: | Not more than 75% |
| NII Quota: | Not more than 15% |
| DRHP Draft Prospectus: | Click Here |
| RHP Draft Prospectus: | Click Here |
| Anchor Investors List: | Click Here |
Senores Pharmaceuticals IPO Lot Size:
The minimum market lot for the Senores Pharmaceuticals IPO is 38 shares, with an application amount of ₹14,858. Retail investors can apply for up to 13 lots, totaling 494 shares, which would require an investment of ₹1,93,154.
| Application | Lot Size | Shares | Amount |
| Retail Minimum | 1 | 38 | ₹14,858 |
| Retail Maximum | 13 | 494 | ₹1,93,154 |
| S-HNI Minimum | 14 | 532 | ₹2,08,012 |
| B-HNI Minimum | 68 | 2,584 | ₹10,10,344 |
Senores Pharmaceuticals IPO Timeline:
The Senores Pharmaceuticals IPO will open on December 20 and close on December 24. The IPO allotment will be finalized on December 26, with the listing scheduled for December 30.
| IPO Open Date: | December 20, 2024 |
| IPO Close Date: | December 24, 2024 |
| Basis of Allotment: | December 26, 2024 |
| Refunds: | December 27, 2024 |
| Credit to Demat Account: | December 27, 2024 |
| IPO Listing Date: | December 30, 2024 |
Senores Pharmaceuticals IPO GMP Today:
The Grey Market Premium (GMP) for the Senores Pharmaceuticals IPO stands at ₹220. Given the upper price band of ₹391 per share, this suggests an estimated listing price of ₹611 per share, indicating a potential gain of approximately 56.27% upon listing.
Promoters of Senores Pharmaceuticals IPO
The promoters of Senores Pharmaceuticals are Swapnil Jatinbhai Shah and Ashokkumar Vijaysinh Barot.
About Senores Pharmaceuticals IPO
Senores Pharmaceuticals is a leading company specializing in the production of generic medicines, certified by global food and drug authorities. The company is committed to offering high-quality products and is focused on meeting the growing demand in the global healthcare sector.
With a strong emphasis on innovation, production, and manufacturing, Senores aims to make healthcare more affordable and accessible, particularly across a wide range of products. The company’s dynamic strategy allows them to identify, produce, and offer specialty, underpenetrated, and complex pharmaceutical products that have earned the trust and reliability of customers worldwide.
While Senores Pharmaceuticals focuses heavily on the US and Canadian markets, its presence extends to 43 countries. The company also manufactures critical care injectables and active pharmaceutical ingredients (APIs), further diversifying its portfolio.
Senores Pharmaceuticals IPO Company Financial Report
The company reported revenue of ₹217.34 crores in 2024 against ₹39.02 crore in 2023. The company reported loss of ₹32.71 crores in 2024 against Profit of ₹8.43 crores in 2023.
Amount ₹ in Crores
| Period Ended | Revenue | Expense | Profit After Tax | Assets |
| 2022 | ₹14.63 | ₹13.49 | ₹0.99 | ₹59.15 |
| 2023 | ₹39.02 | ₹26.58 | ₹8.43 | ₹131.05 |
| 2024 | ₹217.34 | ₹192.40 | ₹32.71 | ₹621.88 |
| September 2024 | ₹183.35 | ₹153.95 | ₹23.94 | ₹678.08 |
Senores Pharmaceuticals IPO Valuation – FY2024
Check Senores Pharmaceuticals IPO valuations detail like Earning Per Share (EPS), Price/Earning P/E Ratio, Return on Net Worth (RoNW), and Net Asset Value (NAV) details.
| KPI | Values |
| ROE: | 23.60% |
| ROCE: | 11.73% |
| EBITDA Margin: | 20.70% |
| PAT Margin: | 15.25% |
| Debt to equity ratio: | 1.07 |
| Earning Per Share (EPS): | ₹13.67 (Basic) |
| Price/Earning P/E Ratio: | N/A |
| Return on Net Worth (RoNW): | 23.60% |
| Net Asset Value (NAV): | ₹66.96 |
Peer Group Comparison
| Company | EPS | PE Ratio | RoNW % | NAV | Income |
| Ajanta Pharma Limited | 64.82 | 34.37 | 23.47% | 281.60 | 4208.71 Cr. |
| Alembic Pharmaceuticals Limited | 31.33 | 34.58 | 13.40% | 245.12 | 6228.63 Cr. |
| Caplin Point Laboratories Limited | 60.79 | 25.23 | 21.69% | 309.03 | 1694.10 Cr. |
| Gland Pharma Limited | 46.90 | 43.73 | 9.26% | 529.65 | 5664.72 Cr. |
| Strides Pharma Science Limited | (7.76) | NA | (4.44%) | 225.43 | 4051.12 Cr. |
Senores Pharmaceuticals IPO Registrar
Link Intime India Private Limited
Phone: +91 8108114949
E-mail: senorespharma.ipo@linkintime.co.in
Website: https://linkintime.co.in/initial_offer/
IPO Lead Managers aka Merchant Bankers
- Equirus Capital Private Limited
- Ambit Private Limited
- Nuvama Wealth Management Limited
Company Address
Senores Pharmaceuticals Limited
1101 to 1103,
11th floor, South Tower, ONE 42
Opposite Jayantilal Park,
Ambali Bopal Road, Ahmedabad,
Ahmedabad, Gujarat,
India, 380054
Phone: +91 -79-29999857
Email: cs@senorespharma.com;
Website: www. senorespharma.com
Senores Pharmaceuticals IPO FAQs
What is Senores Pharmaceuticals IPO?
Senores Pharmaceuticals IPO is a mainboard IPO in which the company aims to raise ₹582.11 crores. The issue is priced between ₹372 and ₹391 per equity share, and it will be listed on both BSE and NSE.
When will Senores Pharmaceuticals IPO open for subscription?
The IPO will open for subscription on December 20, 2024, for Qualified Institutional Buyers (QIB), Non-Institutional Investors (NII), and retail investors. The IPO will close on December 24, 2024.
What is Senores Pharmaceuticals IPO investors’ portion?
The IPO allocation for investors is as follows:
- QIB: 75%
- NII: 15%
- Retail: 10%
How to apply for the Senores Pharmaceuticals IPO?
You can apply for the Senores Pharmaceuticals IPO through the ASBA (Application Supported by Blocked Amount) process online via your bank account. Additionally, you can apply using UPI through your stock broker. Alternatively, you can apply by filling up an offline form via your stock broker.
What is the Senores Pharmaceuticals IPO issue size?
The total issue size for the Senores Pharmaceuticals IPO is ₹582.11 crores.
What is the Senores Pharmaceuticals IPO price band?
The price band for the Senores Pharmaceuticals IPO is ₹372 to ₹391 per share.
What is the Senores Pharmaceuticals IPO lot size?
The minimum bid for the IPO is 38 shares, amounting to ₹14,858.
What is the Senores Pharmaceuticals IPO allotment date?
The IPO allotment date is December 26, 2024.
What is the Senores Pharmaceuticals IPO listing date?
The IPO is expected to list on BSE and NSE on December 30, 2024.
